Objective

Rare diseases are often complex and may require targeting of multiple pathways using drug combinations to achieve clinical responses.

However, the potential number of pairwise drug combinations that could be tested using approved and experimental drugs is large.

Therefore, robust in vitro cellular screening platforms are key for the rapid identification and prioritization of both efficacious monotherapies and combinations.

To address this need Horizon has spent over 15 years developing and industrializing its cellular HTS platform (formerly the CombinatoRx screening platform) for the analysis of small molecules and biologics as single agents or in combination.